US-based conglomerate 3M has completed the acquisition of wound care solutions provider Acelity and its KCI subsidiaries globally for around $6.7bn.
3M acquired the firm from a consortium of funds advised by Apax Partners, along with the Canada Pension Plan Investment Board (CPPIB) and the Public Sector Pension Investment Board (PSP Investments).
The deal, announced in May, is part of 3M’s strategy to boost its presence in advanced and surgical wound care.
Researchers from the Abramson Cancer Center of the University of Pennsylvania have found that liquid biopsy can help to predict the prognosis of glioblastoma(GBM), the most aggressive and common brain cancer in adults.
The study indicated that patients with a higher concentration of cfDNA have shorter progression-free survival than those with less cfDNA. Furthermore, cfDNA increases in patients either at the time of or just before their disease progresses.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Liquid biopsy was compared with the genetic sequencing of solid tissue biopsies in GBM cases.
Dassault Systèmes has completed its acquisition of Medidata Solutions, which will now operate as a Dassault Systèmes brand powered by the 3DEXPERIENCE platform.
The 3DEXPERIENCE platform is a business experience platform which exists to manage the design, production and support of products across multiple industries.
Connecting 3DEXPERIENCE with Medidata’s Clinical Trial platform will help clinicians connect the dots between research, development, manufacturing, clinical trials and commercial deployment throughout the health ecosystem.
The first saliva test to detect if someone has recently taken the drug known as ‘spice’ has been developed at the University of Bath.
The saliva test can be completed on the spot and takes about five minutes. It can identify whether spice has recently been smoked, and if so which variant it has come from and how concentrated the dose was.
Spice poses a significant risk to public health, but there is currently no point-of-care test to see if someone has recently taken it. The team that developed the test hopes it can be used by health professionals to treat people suffering from adverse effects of the drug.
Berlin-based Siemens Healthineers has closed its $1.1bn acquisition of US-based Corindus Vascular Robotics.
Corindus manufactures robotic systems for minimally invasive procedures, while Siemens’ products use quality imaging before and during medical interventions to make minimally invasive treatment possible.
At a shareholders’ meeting held last week, 87.5% of its stockholders approved the acquisition.
US-based medical devices maker Abbott Laboratories has announced plans to build a manufacturing facility in Indiana, a move that is expected to create over 450 jobs.
To be built in two phases, development of the manufacturing facility will complete by the end of 2024. Westfield City Council approved its incentive package.
Westfield Mayor Andy Cook said: “This is a great day for the City of Westfield. We have worked hard to attract diverse businesses. The addition of a Fortune 500 life sciences company, like Abbott, is a big win not only for Westfield but for the state of Indiana.
A clinical trial principally funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has found an artificial pancreas system could effectively control blood glucose levels in patients with type 1 diabetes.
The closed-loop system, Control-IQ, combines Tandem Diabetes Care’s t:slim X2 insulin pump with Dexcom’s G6 continuous glucose monitor. It is designed to automatically monitor blood glucose levels and adjust insulin delivery.
The insulin pump within the system contains advanced control algorithms which leverage a mathematical model, capturing the user’s glucose monitoring data to automatically adjust the insulin dose.
Bayer has partnered with UK-based clinical artificial intelligence (AI) technology company Sensyne Health to create AI-enabled radiology and imaging solutions.
The companies will work under Bayer’s LifeHub UK, which forms part of the German healthcare company’s network of LifeHubs.
LifeHub UK has been launched to facilitate the development of AI-enabled imaging tools to speed-up and optimise disease diagnosis and data-driven discovery of drugs.
Murdoch Children’s Research Institute (MCRI) in collaboration with Lineagen, a Utah-based diagnostic genetic testing and clinical information services company, has developed a new test called Methylation Specific Quantitative Melt Analysis, for the more accurate and timely diagnosis of Fragile X syndrome.
Fragile X syndrome is a common genetic cause of intellectual disability and autism spectrum disorder.
This syndrome impacts about one in 4,000 children. Approximately 90,000 Australians and over one million Americans are impacted in some way by this syndrome.
An international alliance comprising UK and US scientists has been launched with more than £55m in financial support to develop strategies and technologies to boost the detection of cancers at an early stage.
The International Alliance for Cancer Early Detection (ACED) is a partnership between Cancer Research UK, Canary Center at Stanford University, the University of Cambridge, the OHSU Knight Cancer Institute, UCL and the University of Manchester.
Researchers believe that advancements in technologies will help to diagnose cancers at an early stage.
Fitbit has partnered with Bristol-Myers Squibb-Pfizer Alliance (BMS-Pfizer Alliance) to boost early detection of atrial fibrillation (AFib) in those with an increased risk of stroke.
The partners will develop educational content and guidance to support individuals at increased AFib risk.
Fitbit plans to seek US Food and Drug Administration (FDA) clearance for the AFib detection software on its devices.